Physicians can reduce the risk of<unk> S by monitoring of FSH therapy to use this medication judiciously, and by withholding hCG medication. Cabergoline confers a significant reduction in the risk of<unk> S in high risk women according to a Cochrane review of randomized studies, but the included trials did not report the live birth rates or multiple pregnancy rates. Cabergoline, as well as other dopamine agonists, might reduce the severity of<unk> S by interfering with the VEGF system. A systematic review and meta-analysis concluded that prophylactic treatment with cabergoline reduces the incidence, but not the severity of<unk> S, without compromising pregnancy outcomes. The risk of<unk> S is smaller when using GnRH antagonist protocol instead of GnRH agonist protocol for suppression of ovulation during<unk><unk> . The underlying mechanism is that, with the GnRH antagonist protocol, initial follicular recruitment and selection is undertaken by endogenous endocrine factors prior to starting the exogenous<unk> , resulting in a smaller number of growing follicles when compared with the standard long GnRH agonist protocol. A Cochrane review found administration of hydroxyethyl starch decreases the incidence of severe<unk> S. There was insufficient evidence to support routine cryopreservation and insufficient evidence for the relative merits of intravenous albumin versus cryopreservation. Also, coasting, which is<unk><unk>  without induction of final maturation, does not significantly decrease the risk of<unk> S. Volume expanders such as albumin and hydroxyethyl starch solutions act providing volume to the circulatory system
Ovarian hyperstimulation syndrome
Gonadotropin-resistant ovary syndrome
Postpartum physiological changes
Obstetric transition
Anovulation
Puppy pregnancy syndrome
Cryptic pregnancy
Lactational amenorrhea